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The prion protein PrP is a naturally occurring polypeptide that becomes
transformed from a normal conformation to that of an aggregated form,
characteristic of pathological states in fatal transmissible spongiform
conditions such as Creutzfeld–Jacob Disease and Bovine Spongiform
Encephalopathy. We report the crystal structure, at 2 A˚ resolution, of
residues 123–230 of the C-terminal globular domain of the ARQ allele of
sheep prion protein (PrP). The asymmetric unit contains a single molecule
whose secondary structure and overall organisation correspond to those
structures of PrPs from various mammalian species determined by NMR.
The globular domain shows a close association of helix-1, the C-terminal
portion of helix-2 and the N-terminal portion of helix-3, bounded by the
intramolecular disulphide bond, 179–214. The loop 164–177, between b2
and helix-2 is relatively well structured compared to the human PrP
NMR structure. Analysis of the sheep PrP structure identifies two possible
loci for the initiation of b-sheet mediated polymerisation. One of these
comprises the b-strand, residues 129–131 that forms an intra-molecular
b-sheet with residues 161–163. This strand is involved in lattice contacts
about a crystal dyad to generate a four-stranded intermolecular b-sheet
between neighbouring molecules. The second locus involves the region
188–204, which modelling suggests is able to undergo a partial a! b
switch within the monomer. These loci provide sites within the PrPc
monomer that could readily give rise to early intermediate species on the
pathway to the formation of aggregated PrPSc containing additional inter-
molecular b-structure.
q 2004 Elsevier Ltd. All rights reserved.
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The prion protein PrP occurs in a wide range of
eukaryotic cells but its normal physiological func-
tion is unknown. However, mutant PrPs are
associated with the development of transmissible
spongiform encephalopathies (TSE). Notable
examples of TSE include the bovine disease (BSE)
and, in humans, new variant CJD. While an
infectious agent has not been conclusively identi-
fied, the evidence suggests that the characteristics
of the disease are defined in part by the sequence
of the infecting prion.1,2 The molecular mechanism
by which prion diseases develop is thought to
involve a transformation from the molecule’s nor-
mal cellular conformation (PrPc) to an aggregated
species, the scrapie form (PrPSc), also reviewed by
Caughey.3 This aggregate, which develops into the
characteristic plaque found in the brain of infected
individuals, has a significantly higher proportion
of b-sheet than observed in PrPc, but relatively
little is known about how this or the remaining
helical structure is organised. Thus, in spite of
intense research into the conformational behaviour
of the molecule, the nature of the structural change
that converts PrPc to PrPSc, and the mechanism of
infection remain unknown.4 The paucity of such
information seriously limits attempts to under-
stand the disease process and thus restricts the
development of a rational approach to diagnosis
and therapy. Since PrPc itself is a potential target
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for pharmacological intervention, high resolution
structural information is essential for design and
evaluation of appropriate therapeutic agents.
There have been extensive NMR studies on the
solution structure of PrP (reviewed5) while, by
contrast, the X-ray crystallographic approach has
been limited by difficulties in crystallising the
protein. However, the crystal structure of a
truncated mutant of human PrP has recently been
reported.6 Surprisingly, this work showed that a
covalently linked dimer had been formed,
apparently during the crystallisation process. We
report here the crystal structure of residues
121–231 of the monomeric form of the C-terminal
domain of the sheep prion protein. This domain
has been intensively studied by physical and
structural methods (reviewed in Refs. 5,7). It is
known to support transmission of neuropathologi-
cal conditions in transgenic mice8,9 and in further
truncated forms it is itself toxic, causing ataxia
and cerebral degeneration.10 Given the evidence
that the structural transition of prion protein
from its normal conformation to its amyloid
structure is accompanied by a significant increase
in b-sheet11 – 14 we have examined our crystallo-
graphic model to identify segments of the sheep
PrP sequence with the potential to form extended
b-sheet structure. We then consider how the PrP
molecule may utilise such b-structural elements
in initiation of the self-association of PrP leading
to the formation of PrP fibrils typical of TSE
diseases.
Plasmid construction and protein purification
The sequences of sheep, human and hamster PrP
are closely similar, but have different numbering.
For simplicity, the hamster numbering scheme is
applied throughout; thus the disulphide is
Cys179 ! Cys214, except for specific reference to
the sheep sequence, for which italicised numbering
is used.
The plasmid encoding ovPrP(94-233), ARQ
allele, with an N-terminal linker containing a His6
tail was described previously.15 The naturally
occurring mutation, R151C, was introduced using
the following oligonucleotides; 50-CGTTACTGAT
ACTCCTGACAATGATAGCACTTTTG-30 and 50-
CAAAAGTGCTATCATTGTCAGGAGTATCAGT
AACGG-30 via the QuikChange Site Directed Muta-
genesis system (Stratagene). The integrity of the
gene sequence was verified by DNA sequencing.
The resulting protein, ovPrP(94-233) R151C, was
expressed, purified, refolded and re-oxidised as
described previously for doppel proteins. This
refolding method results in the formation of the
native internal disulphide bond, with the novel
cysteine residue protected by a mixed disulphide
with glutathione, as confirmed by mass spec-
trometry. The protein is non-glycosylated, and
lacks the GPI anchor. Protein concentration was
determined spectrophotometrically using the
calculated molar extinction coefficient at 280 nm of
21,170 M21 cm21.16 SDS PAGE gels of the stock pro-
tein solution after storage revealed that, as with the
human PrP protein,6 the molecule His6-PrP(90-231)
had undergone proteolytic cleavage. Mass spec-
troscopy suggests that the truncation occurs
initially at residue His111, and eventually yields
Gly119 ! Ala231 as the major product.
Crystallisation and data collection
Initial crystal screening experiments using the
automated microbatch technique (IMPAX 1-5
robot, Douglas Instruments) yielded tiny clusters
and plates in several conditions with various salts
(i.e. sodium citrate, sodium malonate, ammonium
sulphate, sodium/potassium phosphate) as
precipitant. Optimisation of these conditions was
achieved using the hanging-drop vapour-diffusion
technique. Drops (1 ml) were set up at a protein
concentration of 7 mg/ml and mixed with an
equal volume of reservoir solution. Thin plate-like
crystals grew from sodium potassium phosphate
solutions over the range 0.8–1.3 M (pH 7.4–8.6).
Data were initially collected in-house on a crystal
grown from 0.9 M phosphate (pH 8.6) at 10 8C and
flash-frozen in liquid nitrogen after serial transfer
into mother liquor augmented with 25% glycerol
as cryoprotectant. High-resolution data were sub-
sequently collected from the same crystal at SRS,
Daresbury. Data were integrated and scaled using
DENZO and Scalepack, respectively.
Structure determination, refinement and
associated modelling
The crystals of sheep PrP(121-231) grew in a
plate-like habit and diffracted to better than 2 A˚
Bragg spacing. A data set that was 93% complete
overall (20–2.05 A˚) was collected at SRS,
Daresbury. The structure of these crystals was
solved by molecular replacement using AMORE,17
based on the crystal structure of the human prion
protein, 1I4m6 as a search model. In the first step
of the molecular replacement calculation the
C-terminal helix (residues 195–230) was omitted
from the search model because of its role in
“swapping over” with the corresponding helix in
the human PrP dimer. This helix was subsequently
positioned within the monomer by rigid-body
fitting after least-squares superposition with the
corresponding segment established by NMR
analysis. The structure was built using O18 and
refined using a combination of REFMAC519 and
CNS.20 Crystallographic statistics are presented in
Table 1. Subsequent modelling calculations,
unrestrained by X-ray terms, were carried out
using the CHARMM program21 utilising the
toph19/param19 potential.22 Energy minimisations
were carried out using combinations of steepest
descent and adopted basis Newton Raphson
methods.21
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The crystal structure of sheep PrP
globular domain
The sheep protein has approximate dimensions
of 55 A˚ £ 35 A˚ £ 25 A˚, and the crystals contain
45% solvent. The domain contains three helices
(helix-1: 143–154; helix-2: 172–194; helix-3: 200–
225), and one short segment of double-stranded
anti-parallel b-sheet (129–131:163–161). The tem-
perature factors (Figure 1) indicate that helices 1,2
and 3 are all well defined, and that a relatively
compact core is formed by helix-1, the C-terminal
region of helix-2 and the N-terminal region of
helix-3. The latter two elements are limited by the
intramolecular disulphide bond linking Cys179 to
Cys214, which has an SS dihedral angle of 2908.
The N-terminal segment prior to residue 123 is
partially disordered and residues 124–137 have
relatively high thermal factors. There is evidence
from the difference electron density for alternative
conformations between 132 and 137. The sub-
sequent sequence was built continuously as far as
residue 230.
Overall the electron density maps are of good
quality as is illustrated by the omit density for a
single [HPO4]
22 ion. (Preliminary results suggest
this ion is only weakly bound.) This ion is located
between helices 1 and 3. It forms salt bridges to
Arg208 and Lys204, and makes hydrogen bonds to
Glu146 (carboxylate) and to two amide main-chain
nitrogen atoms at 142 and 143, as shown in
Figure 2A. An additional side-chain salt bridge is
seen at Asp147:Arg151; the interaction
Arg164:Gln168 (sheep PrP) is present in the
human prion as a salt bridge, Arg164:Glu168. The
salt bridge Arg148:Glu152 present in the human
PrP dimer, is absent from the sheep PrP structure,
owing to the inclusion of the mutation Arg148Cys.
A number of water molecules, some partially
buried, have been identified, mediating hydrogen
bonds that presumably help stabilise this confor-
mation of the PrPc molecule.
Comparison with human dimer
Figure 2B shows the conformation of the sheep
prion protein C-terminal segment for comparison
with that of the dimeric form of human
Table 1. Crystallographic statistics
Space group P21212
Unit cell (A˚) a ¼ 85:1, b ¼ 29:0, c ¼ 45:9
Resolution (A˚) 20–2.05
Completeness (%) 93.2 (83.7)
Rsym: (%) 10.3 (46.5)
Rwork (%) 27.3
Rfree (%) 31.9
rms bonds (A˚) 0.007
rms angles (8) 1.2
The values in parenthesis are for the highest resolution bin
(2.12–2.05 A˚). The final dataset, for which the parameters
above apply, include a low-resolution pass as well as the higher
resolution data collected at the SRS. The low resolution set was
collected in-house on a Raxis II detector with the same crystal
later used for the SRS collection. Merging of both sets of data
adds ca 2% to Rsym but significantly enhances the completeness
of the intense, low resolution terms and, perhaps unsurpris-
ingly, produces better quality electron density maps. This factor
likely accounts for the crystallographic refinement statistics
being somewhat higher than would be expected given the
quality of the electron density maps.
Figure 1. Stereo view of residues 123–230 of the crystal structure of the globular domain of sheep PrP showing the
secondary structural elements, and intramolecular cystine bridge. The colour coding represents the experimentally
determined temperature factors (Figure drawn with Bobscript).
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PrP(119-231) (Figure 2C), obtained from crystals
grown under conditions containing 3 M NaCl (pH
8.3).6 In this structure, helix-3 is swapped
between two PrP molecules, so that the structure
of both helices and the local interactions in the
monomer are preserved. This unusual structural
reorganisation requires the exchange of the
179–214 disulphide bond that links helices 2 and
3, from an intramolecular to intermolecular
configuration with the same chirality as in the
monomer. The dimer molecule also contains an
intermolecular anti-parallel b-sheet through
residues 190–194, and the corresponding segment
related by crystal symmetry. In the monomeric
sheep PrP structure, these residues are part of the
C-terminal end of helix-2. The dimerisation in
the human PrP structure and the formation of the
intermolecular b-sheet is dependent on the partial
unwinding of the C-terminal end of helix-2. This
is therefore, a limited a! b transition, restricted
to this local region.
In the human and sheep prion crystal
structures the extended loops have distinctive
properties. In the human prion C-terminal domain
the N-terminal segment 119–135 is relatively
ordered, a consequence of its crystal contacts,
while the segment 190–194 involved in the inter-
molecular b-sheet contacts has high thermal
factors. In the sheep PrP the pattern is reversed,
the segment 121–135 has high thermal factors,
whereas the segment 190–195 (helix-2 in the
sheep PrP) is well defined. This contrasting pattern
of behaviour is not completely explained by crystal
contacts. In the case of the human prion the
N-terminal residues do make crystal contacts but
without forming b-sheet structure. Curiously in
both crystal structures the extended loops are
relatively poorly ordered when they are participat-
ing in b-strands.
The a! b conversion process of PrP itself is
most frequently observed in vitro in the range pH
4–723 – 26 and has been postulated to be induced in
vivo due to the low pH of endosomal
compartments.27,28 Such conditions appear unlikely
to induce disulphide reduction or exchange under
physiological conditions, and such reactions do
not appear to be a necessary requirement for PrPSc
formation.29 However, the observations that the
structure adopted by residues from 188 to 200 in
the human PrP appears to be of lower relative
stability compared to the rest of the structure,
suggesting that a group of four threonine residues
within this segment has an intrinsic propensity to
undergo a local a! b transition. This suggests the
feasibility of this a! b transition occurring under
conditions that promote PrPSc formation, inde-
pendent of a disulphide exchange reaction. This
region could then be an additional locus for
b-structure nucleation.
Comparison with NMR structures
The structures of PrP protein constructs from
numerous mammalian species have been reviewed
in detail.5 There are relatively few sequence differ-
ences between the sheep/human PrP domain, and
these are mainly conservative changes, i.e.
138Leu/Ile; 143Asn/Ser, 166Val/Met, 168Gln/Glu;
185Val/Ile; 204Ile/Val, but including 155His/Tyr
with a more significant difference in side-chain.
Figure 3 shows the recent NMR structure of the
human PrP C-terminal domain,30 compared to the
crystal structure of the sheep PrP domain. Least-
squares superposition of Ca atoms of residues
125–225 of the representative human PrP NMR
structure (1hjm.pdb) and the sheep crystal struc-
ture shows an rms difference of 1.79 A˚, but there
is a closer similarity in secondary structure. The
three helices H1–H3 together superpose with an
rms difference of 1.41 A˚ (52 Ca atoms), while the
pairwise superposition of helices yields rms values
Figure 2. A, Portion of a CNS all omit map covering
the vicinity of the phosphate ion linking the segment of
the polypeptide at the immediate N terminus of helix-1
with the middle section of helix-3. (Liganding to Glu146
is not shown for clarity, see the text.) B, Schematic
representation of the sheep PrP molecule. The helices,
labelled H1–H3, are shown in blue, and the short seg-
ments of anti-parallel b-sheet are shown in red. C,
Schematic representation of the helix-swapped dimer
structure of the human prion protein.6 The bottom half
of the dimer is in the same orientation as the sheep PrP
shown in B and similarly coloured, but with H3 in light
blue. The dyad-related monomer is at the top and its
b-strands are coloured in green. The helices for the
dyad-related molecule are distinguished by a prime.
The exchange of H3 and H30 is accompanied by the for-
mation of an additional segment of anti-parallel b-sheet,
coloured in red and green (Figure drawn with Spock).
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of 0.95 A˚ (H1–H2, 26 atoms), 1.22 A˚ (H2–H3, 43
atoms), and 1.37 A˚ (H1–H3, 35 atoms). The main
contribution to these differences is that the initial
residues of helix-2 at the N terminus of sheep PrP
are more regular than comparable residues in the
human PrP NMR structure, and the C-terminal
structure of helix-3 is somewhat more curved in
the crystal structure, than is seen in this, and other
NMR structures. Small differences are also evident
in the helix packing. The polypeptide loops linking
the helices are similar in overall position, but show
significant variation in conformation. There is
particular interest in the loop between the second
b-strand (161–163) and the start of helix-2. This
loop segment, relatively poorly defined by NMR
and showing intermediate values of backbone
thermal factors in the sheep (and human) crystal
structures, has been postulated to be the region of
additional protein–protein interactions, potentially
those involving protein-X, postulated as a facili-
tator of the PrPc ! PrPSc conversion.31 – 33 There are
other considerable variations between the NMR
and X-ray structure determinations for residues at
either N or C termini, and also at the side-chain
level for the S–S bridge. Further comparisons are
limited by the absence of water molecules in the
NMR determined structures; a number of side-
chain conformations are likely to be affected by
solvent packing and H-bond contacts.
Potential b-strand polymerisation sites
There are two specific observations from the
available crystallographic structures of PrPc that
may be relevant to the development of b-sheet con-
taining oligomeric species during the formation of
the aggregated PrPSc form. First, from the sheep
PrP crystal structure we find that the segment
129–131 forms an anti-parallel b-sheet with a sym-
metry-related molecule (see Figure 4A). By means
of this crystallographic symmetry interaction, the
two-stranded anti-parallel b-sheet in each molecule
(129–131 and 161–163) becomes a four-stranded
anti-parallel sheet extending across two molecules.
The dimer contact region is relatively flexible and
largely polar, with the most significant contact
being that between the two symmetry-related
Met129 residues. This observation suggests that
the 129–131 segment of the sheep PrP could
represent a potential locus (L1) for further b-
structure development, and hence help to nucleate
b-mediated intermolecular interactions in vivo.34
Intriguingly, there is an exclusive correlation
between the occurrence of the human disease,
new variant CJD, and the homozygous expression
of the Met129 isoform of PrP.35
Secondly, as described above, the dimeric struc-
ture of human PrP shows monomers interacting
through a b-sheet created by a local change in
conformation.6 The highly conserved amino acid
sequence, residues 188–201 (TVTTTTKGENFTET)
has several interesting features that appear
relevant to this region undergoing a change in con-
formation under suitable perturbing conditions. It
contains seven threonine residues; the four con-
secutive threonine residues contribute to the
b-sheet segment in the human PrPc structure. In
the sheep PrPc structure, these residues, plus
Thr188, all make hydrogen bonds with the main-
chain carbonyl groups of helix-2, potentially
strengthening what may otherwise be a relatively
unstable structure. The hydroxyl of Thr199 hydro-
gen bonds to the peptide NH of 201–202 in helix-
3, while that of Thr201 is directed away from the
helix into solution. In contrast with sheep PrP, in
the human PrP structure helix-2 terminates at
residue 190, with Thr191, Thr192 and Thr193
located on the b-strand, with their side-chains
directed into solvent. The hydrogen bonding of
Thr199 hydroxyl is to the swapped helix-3. The
potential of these threonine residues to make
different networks of hydrogen bonds, as seen in
the sheep and human PrP structures, may facilitate
the shift in this local a! b conformation. The fact
that the seven threonine residues are invariant
across a wide variety of species36 suggests a func-
tional role, possibly in facilitating localised confor-
mational plasticity in this part of the PrP
molecule. This leads us to propose that, under
suitable perturbing conditions, residues 188–200
of the monomeric sheep PrP molecule may be
restructured so that residues 190–194 adopt a
b-strand conformation, while retaining the
Figure 3. Comparison of the crystal structure of the
globular domain of the ARQ allele of sheep PrP (blue)
and the NMR structure of human PrP (yellow:
1hjm.pdb): least-squares superimposition of common
residues, with an rms difference ¼ 1.73 A˚ for 100 Ca
atoms. In addition to the three helices, the intramolecular
b-sheet (arrows, b1:129–131; b2:161–163) is shown in
red for sheep PrP, and grey for human PrP. The YYR epi-
tope is at 162–164. The loop 164–174 between b2 and
H2, is shown in green for sheep PrP. The three poly-
morphic residues of sheep (A133,R151,Q168), are shown
in magenta (Figure drawn with Spock).
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similarity in position of helix-3 between the sheep
PrP structure and that seen in the helix-swapped
model of the human PrP.
We have tested this possibility, using molecular
modelling of the PrP monomer structure. The
Thr190–Thr199 segment was reoriented such that
residues Thr190–Thr193 followed the trace of the
corresponding residues in the human PrP dimer
structure, generating a second b-strand locus (L2)
(Figure 4B). The remaining segment (Lys-194 to
Thr-199) was allowed to relax to a local minimum
using constrained energy minimisations, applied
to a dimer of the restructured sheep monomer,
generated using transformations derived from the
human structure. The procedure establishes that
the local a! b change can indeed be incorporated
in the monomeric structure without perturbing
helix-3. A dimer of the restructured sheep mono-
mer was generated from the human PrP dimer
model, showing that a non-covalent dimer of a
modified sheep PrP structure can in principle be
generated through a b-strand interface, using
residues 190–193.
The new dimer of “modified monomers” of
sheep PrP (see molecules coloured blue and yellow
in Figure 4C) is a flat structure with approximate
dimensions of 80 A˚ £ 60 A˚ £ 25 A˚. It has two
exposed b-strands, centred on Met129 and labelled
L1, that were described earlier as mediating lattice
contacts in the sheep PrP crystal structure. Appli-
cation of the crystal dyad transformation observed
in the sheep PrP to the modified dimer structure
at L1 generates a tetramer as shown in Figure 4C,
which could in principle undergo further
oligomerisation.
Discussion
The structure of the sheep prion protein is the
first monomeric PrP structure to be obtained by
X-ray crystallography. It is of particular interest in
view of the fact that scrapie, the disease of sheep,
predates the more recent identification of TSEs by
more than 200 years.37 The absence of evidence of
an infection of humans from sheep was taken to
indicate a species-specific barrier that prevented
transmission of the disease via the human food
chain. Our results show that the structure of the
globular domain of sheep PrP correlates quite
closely with structures of many other species,
including the human PrPc. Thus there is no detect-
able structural property of the cellular form of
sheep PrP that might account for its lack of trans-
missibility to humans.
It is widely recognised that numerous proteins,
Figure 4. A, Schematic represen-
tation of the crystallographic dyad-
mediated lattice contact between
two monomers in the sheep PrP
crystals. The four-stranded anti-
parallel b-sheet is coloured in
green and labelled locus L1. B,
Schematic representation showing
the superposition of three struc-
tures in the region linking helices 2
and 3: the helix-swapped human
PrP dimer (yellow), the sheep PrP
crystal structure (white, this
paper), and the remodelled sheep
PrP (red), see the text. The segment
of b-strand, present in the human
PrP structure, and modelled into
sheep PrP, is coloured in green,
and marked as the L2 locus. C,
Two orthogonal views of a tetramer
of sheep PrP molecules generated
through the two b-mediated loci.
The mauve and blue coloured
monomers (with b-sheet coloured
green), as well as the red and
yellow pair, are generated by the
crystallographic dyad in the sheep
PrP crystal structure and the inter-
face is marked as the L1 locus. The
blue and yellow pairs are generated
by remodelling and symmetry
generation based on that observed
in the human PrP crystal structure.
This second association is mediated
through the L2 locus (Figure
drawn with Ribbons).
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and polypeptide sequences derived from them, can
polymerise through repeated b-strand interactions
to form an amyloid structure.38 In the case of
prion diseases, the aggregated material PrPSc, con-
taining PrP with an enhanced proportion of
b-structure,11 – 14 undergoes partial proteolytic
processing to PrP(27-30), prior to amyloid fibril
formation.39 In addition, the prion diseases are
unique amongst the amyloidoses in being trans-
missible serially between animals, although the
process remains obscure. Thus, although amyloid
fibrils evidently exhibit structural features in
common, there may be different mechanisms of
formation and the fibril structure may not be
identical in all cases.
The identity of distinctive residues in the
globular domain affected by the PrPc ! PrPSc
conversion has been indicated by changes in the
immunological properties of the protein. Epitopes
in the N-terminal region of PrPc (residues 90–120)
become buried in the PrPSc form:40 conversely, a
YYR epitope, probably at 162–164, that is
inaccessible in PrPc becomes accessible in PrPSc.41
Other evidence of the importance of this region
comes from analysis of the protease-resistant PrPSc
material of the related Gerstmann–Strau¨ssler–
Scheinker syndrome as containing peptides of
sequence ,88–153.42 Also a distinctive b-helix
ultra-structure of the region 141–176 is suggested
by imaging of a two-dimensional crystal form
derived from PrP27-30.43 These data indicate the
likely, but not necessarily exclusive, involvement
of residues in the N-terminal and central portion
of the sequence of PrP(90-231) as contributing to
the b-rich region of PrPSc.
The crystal structure of the sheep PrP molecule
reveals two potential loci of b-structure propa-
gation within the monomer. At least two such loci
are necessary for the formation of an open poly-
meric assembly. First, the structure reveals an
important lattice contact involving the b-strand
129–131 (L1). The associated crystallographic
dyad generates a four-stranded, intermolecular
b-sheet. In view of the small number of inter-
molecular contacts at this site, this interface
appears likely to confer only a weak propensity
for dimerisation of PrP in solution. However, we
speculate that this may be an initial contact from
which a more extensive interface develops under
conditions favouring b-structure formation.
Secondly, comparison of our X-ray structure of
sheep PrP with that of the human suggests that a
limited a! b conformational change may
occur in the C terminus of helix-2. Applying
the dimer dyad axis seen in the human PrP
structure to the restructured sheep monomer
generates a non-covalent b-mediated dimer (L2).
Although there are clearly other loci where de novo
b-structure generation could occur, L1 and L2
are two identified sites where b-structure
could be propagated from pre-existing
b-strands within the predominantly a-structured
monomer.
It may be noted that dimerisation of PrP
essentially in the a-form has been reported, follow-
ing treatment of PrP(90-231) with low concen-
trations of detergent at neutral pH, and this non-
covalent association has been postulated to
precede the a! b conversion reaction.44 Either of
the two b regions discussed here could promote
the formation of such a dimer as an intermediate
species in the subsequent overall more extensive
a! b transformation. Quantitatively, this trans-
formation requires a change in conformation of
approximately 18 a-helical residues in the globular
domain, plus any additional residues involved in
de novo b-structure formation.11 – 13 This estimate is
considerably larger than the minimal estimates of
b-structure in the loci L1 and L2. Nonetheless, this
analysis reinforces the potential role of these two
loci as initiators of molecular associations that are
subsequently driven by a more substantial a! b
conformational change. This process corresponds
to the model of nucleated conformational con-
version, as proposed for the involvement of
structurally fluid intermediates acting as nuclei in
prion amyloid formation.45 – 48
In addition, any structural model of fibril for-
mation from PrP must have the spatial ability to
accommodate the N terminus of the PrP(90-231)
molecule, and the post- translational glycosyl
modifications, that occur (at Asn181 and Asn197)
in the physiologically relevant forms of PrP.
Glycosylation has been shown to slow down
fibrillar conversion in a model peptide system,49
consistent with some involvement of the L2 region
in the conversion process.
Overall the crystal structure of sheep PrP
provides the basis for detailed comparison with
other PrP structures, and facilitates the design of
structurally directed experiments to further define
the biochemical and biophysical mechanisms of
PrP conformational conversion and prion disease.
The analysis of the crystal structure of the sheep
PrP, and the associated modelling studies in
comparison with the dimeric structure of human
PrP illustrate the small extent of conformational
adjustment within the monomeric PrPc structure
required to produce a potentially oligomeric
nucleating unit, and this may be important for the
PrP amyloid forming process.
Atomic coordinates
The coordinates have been deposited with the
Protein Data Bank under the ID Code 1UW3.pdb.
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